In the CANTOS phase III trial, canakinumab (anti-IL-1beta) cut cardiovascular events by 15% in post-heart-attack patients with high CRP, but increased fatal infections.
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).